1. Home
  2. IDN vs KLRS Comparison

IDN vs KLRS Comparison

Compare IDN & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellicheck Inc.

IDN

Intellicheck Inc.

N/A

Current Price

$2.02

Market Cap

43.4M

Sector

Technology

ML Signal

N/A

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

N/A

Current Price

$2.39

Market Cap

44.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IDN
KLRS
Founded
1994
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.4M
44.5M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
IDN
KLRS
Price
$2.02
$2.39
Analyst Decision
Buy
Buy
Analyst Count
3
8
Target Price
$4.83
★ $17.67
AVG Volume (30 Days)
★ 238.8K
58.1K
Earning Date
11-12-2026
11-20-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 220.00
75.70
EPS
★ 0.06
N/A
Revenue
★ $4,433,454.00
$165,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$34.83
★ N/A
Revenue Growth
★ 23.21
N/A
52 Week Low
$2.07
$1.78
52 Week High
$9.08
$11.88

Technical Indicators

Market Signals
Indicator
IDN
KLRS
Relative Strength Index (RSI) 30.61 56.30
Support Level N/A N/A
Resistance Level $2.49 $4.37
Average True Range (ATR) 0.15 0.18
MACD -0.03 0.10
Stochastic Oscillator 8.73 79.55

Price Performance

Historical Comparison
IDN
KLRS

About IDN Intellicheck Inc.

Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company includes solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: